TD Asset Management
TVTX icon

TD Asset Management’s Travere Therapeutics TVTX Stock Holding History

TD Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$521K Buy
+17,534
New +$524K ﹤0.01% 1169
2024
Q4 		– Sell
-71,800
Closed -$1.01M – 1402
2024
Q3 		$1.01M Buy
+71,800
New +$748K ﹤0.01% 1183
2018
Q1 		– Sell
-10,800
Closed -$228K – 1372
2017
Q4 		$228K Sell
10,800
-2,600
-19% -$59.4K ﹤0.01% 1291
2017
Q3 		$334K Hold
13,400
– – ﹤0.01% 1223
2017
Q2 		$260K Sell
13,400
-8,200
-38% -$149K ﹤0.01% 1278
2017
Q1 		$399K Sell
21,600
-3,277
-13% -$64.1K ﹤0.01% 1265
2016
Q4 		$471K Sell
24,877
-1,323
-5% -$27.1K ﹤0.01% 1197
2016
Q3 		$586K Buy
26,200
+5,300
+25% +$101K ﹤0.01% 1140
2016
Q2 		$372K Hold
20,900
– – ﹤0.01% 1206
2016
Q1 		$285K Sell
20,900
-1,200
-5% -$18.2K ﹤0.01% 1237
2015
Q4 		$426K Hold
22,100
– – ﹤0.01% 1143
2015
Q3 		$448K Buy
22,100
+600
+3% +$17.8K ﹤0.01% 1095
2015
Q2 		$713K Hold
21,500
– – ﹤0.01% 1035
2015
Q1 		$515K Buy
+21,500
New +$328K ﹤0.01% 1106

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TD Asset Management's TVTX Position: Q1 2026 in Review

TD Asset Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 17,534 shares worth $521K. The stake represents ﹤0.01% of the portfolio and ranks #1169 among its holdings. This is a return to the name: TD Asset Management previously reported a position in TVTX as recently as Q3 2024.

TD Asset Management first reported a position in TVTX in Q1 2015 and has held it in 14 quarters since. The position peaked at $1.01M in Q3 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • TD Asset Management held 17,534 shares of Travere Therapeutics worth $521K as of Q1 2026.
  • Travere Therapeutics was a new TD Asset Management position in Q1 2026.
  • Travere Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1169 holding.
  • TD Asset Management first reported a position in Travere Therapeutics in Q1 2015 and has held it in 14 quarters since.
  • TD Asset Management's Travere Therapeutics position peaked at $1.01M in Q3 2024.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.